Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 1 - 10 of 46 results.

You searched for : May 2020 to May 2021.

Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and D ...

Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer Download the PDF version...

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the ...

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia Download the PDF version of Article May...

Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myelo ...

Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Download the PDF version of Article April 07, 2021...

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Col ...

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer Download the PDF version of Article April 06, 2021 Munich and Basking Ridge, NJ –...

DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Sma ...

DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer Download the PDF version of Article March 29, 2021 Tokyo, Munich and Basking...

Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with ...

Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma Download the PDF version of Article February 24, 2021 Phase 2...

Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D

Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D Download the PDF version of Article February 22, 2021 Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D Tokyo, Munich...

New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Mil ...

New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Million Adults in the U.S. Download the PDF version of Article February 17, 2021 New Survey Reveals...

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with ...

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC Download the PDF version of Article February 03, 2021 HERTHENA-Lung01 Phase 2...

Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research I ...

Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute Download the PDF version of Article February 02, 2021 Daiichi Sankyo Initiates Clinical...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...